Magenta Therapeutics, Inc.MGTANASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank76
5Y CAGR+66.4%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+66.4%/yr
Long-term compound
Percentile
P76
Within normal range
vs 5Y Ago
12.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 21.17% |
| Q3 2025 | -7.60% |
| Q2 2025 | 20.88% |
| Q1 2025 | 52.19% |
| Q4 2024 | -26.15% |
| Q3 2024 | 8.85% |
| Q2 2024 | 0.00% |
| Q3 2023 | 64.03% |
| Q2 2023 | -13.27% |
| Q1 2023 | 3.20% |
| Q4 2022 | -1.82% |
| Q3 2022 | -6.60% |
| Q2 2022 | -11.07% |
| Q1 2022 | 3.71% |
| Q4 2021 | -5.69% |
| Q3 2021 | 14.95% |
| Q2 2021 | -7.00% |
| Q1 2021 | 2.35% |
| Q4 2020 | 3.24% |
| Q3 2020 | -10.90% |
| Q2 2020 | 1.66% |
| Q1 2020 | 22.93% |
| Q4 2019 | -3.22% |
| Q3 2019 | 3.64% |
| Q2 2019 | 1.58% |
| Q1 2019 | 4.93% |
| Q4 2018 | 4.84% |
| Q3 2018 | 21.70% |
| Q2 2018 | 25.60% |
| Q1 2018 | 32.00% |
| Q4 2017 | 45.10% |
| Q3 2017 | -5.74% |
| Q2 2017 | 28.61% |
| Q1 2017 | 0.00% |